BioSpace News Archive

Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today two abstracts featuring ELU001, its lead C’Dot Drug Conjugate (CDC) clinical candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held April 8-13, in New Orleans.

In the recent past, scientists, now part of Halberd, worked with the military to attempt to stem the rash of suicides associated with clinical depression due to PTSD/TBI.

The awareness about mHealth services has significantly increased in the past few years that helps in enhancing the quality of life for individuals afflicted with lifestyle diseases.

Currently, the world is going through some radical changes. Since December 2019, the world has been trying to cope with the Covid-19 outbreak and live and adapt to the lifestyle forced upon us.

The report further provides details about each segments and regions covered in the global Behavioral/Mental Health Software market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

The industry analysis report is considered a valuable source of information about the global Microplate Readers industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Rising Number of Genetic Disorders and Population Genomics is Driving Industry Demand, Says Emergen Research

Rising preference for minimally invasive surgical procedures, increasing investments in research and development activities to develop advanced surgical devices, and rising number of product approvals are some key factors expected to drive global market growth.

Advancements in liquid biopsies, enabling safer, easier and earlier detection of cancer, is the focus of the inaugural S.E.E. Summit, a virtual conference on April 21, 2022.

A federal partnership established to help increase access to COVID-19 vaccines for end stage kidney disease (ESKD) patients receiving dialysis was successful in reducing racial disparities in vaccination coverage, new research published today in JAMA Internal Medicine affirms.